Everything Draft and the Ultimate Pick Party! See Kenny Chesney in Las Vegas Y100’s 2025 Barstool Brackets winner is… Shotgun & Charli Birthday Club Submit your community events here! Wake Up With Shotgun & Charli Farmer of the Month News From The Pack Blog Grab Your Y100 Merch! Take Our Listener Survey St. Jude Jam 20

  • 490articles · 30d
  • 1+ day agolatest article
  • Aug 15, 2026earliest in window
  • 20%with images
  • 301avg words
articles per day
Categories
  • News 158
  • Economy, Business & Finance 126
  • Sports & Fitness 112
  • Politics 111
  • Sports 111
  • Sport 101
  • Finance & Business 95
  • Politics2 80

Please confirm you are human

This browser or connection looks automated. Press and continuously hold the control for 3 seconds to enable Google-hosted web results and, when separately allowed, AI-assisted answers.

A successful check enables 100 search requests. Interactive access does not authorize scraping, systematic collection, or reuse of search output.

Hold with a pointer, or hold Space or Enter.

News

wncy.com
wncy.com > 09/08/2026 > dyne-sarepta-shares-tumble-as-novartis-setback-weighs-on-muscle-disease-drug-developers

Dyne, Sarepta shares tumble as Novartis setback weighs on muscle disease drug developers

5+ day, 16+ hour ago   (317+ words) Sept 8 (Reuters) – Shares of Dyne Therapeutics and Sarepta slumped on Tuesday after Novartis’ treatment for a muscle-wasting disorder failed in a trial, fueling investor concerns ​about the prospects of similar therapies for the tough-to-treat ‌rare disease. Dyne’s stock led declines…...

wncy.com
wncy.com > 09/07/2026 > novo-scraps-two-more-heart-drug-trials-further-dimming-growth-beyond-obesity

Novo scraps two more heart drug trials, further dimming growth beyond obesity

1+ week, 7+ min ago   (191+ words) Sept 7 (Reuters) – Novo Nordisk said on Monday it had halted two additional trials of its ​experimental cardiovascular drug ziltivekimab, further ‌denting the Danish drugmaker’s efforts to diversify beyond its blockbuster obesity and diabetes franchise. In July, Novo said ziltivekimab failed…...